#United States #Anixa Biosciences #San Jose #Cancer Vaccine #lira-cel

Anixa Biosciences Participates in Water Tower Research Insights Conference

Anixa Biosciences, Inc. (NASDAQ: ANIX), a prominent player in the biotechnology industry, is gearing up for a significant moment as it participates in the upcoming Water Tower Research (WTR) Insights Conference on April 14, 2026. The event will take place virtually at 12:30 PM ET, providing attendees with a unique opportunity to gain insights directly from Anixa's leadership.

Overview of the Event

Dr. Amit Kumar, Chairman and CEO of Anixa, will be at the forefront of the presentation. He will discuss a range of topics that highlight the company’s innovative approaches and advancements in cancer treatment and prevention. Notably, the discussion will cover:

• - An overview of Anixa and its business strategy
• - Insights into the breast cancer vaccine that successfully met its primary endpoints, exhibiting crucial immune responses in 74% of participants during Phase 1 clinical trials
• - Updates on the ovarian cancer CAR-T therapy, known as lira-cel, which has demonstrated encouraging survival data in ongoing clinical trials

The WTR Insights Conference aims to foster a rich dialogue between investors and innovators across diverse sectors of the economy. The format features a series of fireside chats and discussions, designed for investors seeking to delve deeper into the strategies and growth potentials of cutting-edge companies.

Importance of Registration

For those interested in the conference, advance registration is highly recommended. Attendees can anticipate access to insightful discussions, the complete agenda, a lineup of participating companies, and opportunities for further engagement post-event. Interested parties can register through the Event Registration link provided by Water Tower Research.

About Anixa Biosciences

Anixa is at the forefront of developing innovative cancer therapies, focusing on groundbreaking solutions to treat and prevent various cancers. Its portfolio includes the ovarian cancer immunotherapy, liraltagene autoleucel (lira-cel), developed in collaboration with the renowned Moffitt Cancer Center.
This therapy distinguishes itself through the application of chimeric endocrine receptor-T cell (CER-T) technology. Unlike traditional CAR-T therapies, which rely on antibody fragments, this approach utilizes the natural ligand of the follicle-stimulating hormone receptor (FSHR) to engage tumor cells effectively.

Additionally, Anixa’s vaccine projects are being co-developed with the Cleveland Clinic with an aim to combat breast and ovarian cancers, while also tackling other significant malignancies, such as lung and prostate cancers. This alliance with major research institutions enables Anixa to leverage expert knowledge and emerging technologies to push the boundaries of cancer treatment.

Conclusion

As Anixa Biosciences continues to progress with its innovative therapies, the upcoming Water Tower Research Insights Conference represents a pivotal opportunity for investors to understand the company's unique value proposition in the biotechnology landscape. With promising clinical trial results and a dynamic business model focused on collaboration with esteemed research entities, Anixa is well-positioned for future growth and success in the fight against cancer.

To learn more about Anixa Biosciences and its transformative initiatives, visit www.anixa.com and connect with them on LinkedIn, X, Facebook, and YouTube.